ESTRO 38 - Programme Book & Exhibition Guide

Welcome letter

On behalf of the Scientific Programme Committee, it is our honour and pleasure to welcome you to ESTRO 38. ESTRO 38 will offer to us all, as professionals of oncology, the chance to share knowledge, practice and advances in the field, within the ever warm and dynamic environment of the ESTRO meetings. ‘Targeting optimal care, together’ will be the theme of ESTRO 38 and through these few, however impactful words, the Scientific and organising committees would like to put a spotlight on the multiprofessional and multidisciplinary aspect of our specialty. The theme also represents our strength: we are all working towards a common goal for improved patient outcomes, and this will be expressed throughout the scientific programme: Targeting: the concept is inherent to the radiation oncology specialty, and certainly well in line with the modern concept of precision medicine. Optimal Care: the value and the cost for radiotherapy are an inseparable part of the equation for optimal treatment. Although the clinical outcome of our patients is the priority in our daily practice, this cannot happen without common efforts to improve the access to treatment for all cancer patients. Together: the radiation oncology community is a mosaic of various

stakeholders: medical and scientific communities, industry, national societies as well as oncology organisations, institutes, patients and advocates. We all join forces. The interdisciplinary component of the scientific programme includes sessions on the following topics: • Artificial Intelligence in radiation oncology: role and potential • Radio-immunotherapy • Adaptive RT guided by early response (adapting the adaptive!) • Adaptive RT: reactive or proactive? • MRmachines and treatment adaptation • Clinical trials for particle therapy: which ones to run and how? • The DNA damage response with radiotherapy • Radiotherapy biomarkers: a confluence of imaging, genetics and pathology • Cardiac substructures and toxicity • Predictive models of toxicity and big data, big open issues • The role of hypofractionation in current radiotherapy and its impact in planning radiotherapy services • Palliation in radiotherapy - How much is enough? • Are adolescents and young adults (AYA) a specific patients’ population? • Plan of the day. General gains of performing • Re-irradiation for breast cancer • Extreme hypofractionation in the treat- ment of localised prostate cancer • Radiotherapy in bladder cancer: standard of care and future perspectives

Programme and Exhibition Guide | GENERAL INFORMATION

9